Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.
Company profile
Website
CEO
Ronald C. Renaud
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
Former names
RaNA Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Translate Bio MA, Inc. • Translate Bio Securities Corporation ...
Latest filings (excl ownership)
15-12B
Securities registration termination
24 Sep 21
EFFECT
Notice of effectiveness
22 Sep 21
EFFECT
Notice of effectiveness
22 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Sep 21
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Sep 21
POS AM
Prospectus update (post-effective amendment)
14 Sep 21
POS AM
Prospectus update (post-effective amendment)
14 Sep 21
POSASR
Automatic shelf registration (post-effective amendment)
14 Sep 21
Latest ownership filings
4/A
SETH A KLARMAN
16 Sep 21
SC 13D/A
BAUPOST GROUP LLC/MA
16 Sep 21
4
Everett Rand Sutherland
14 Sep 21
4
Brendan Smith
14 Sep 21
4
Ronald C Renaud JR
14 Sep 21
4/A
Ronald C Renaud JR
14 Sep 21
4
Paul D. Burgess
14 Sep 21
4
Robert M Plenge
14 Sep 21
4
Robert J. Meyer
14 Sep 21
4
Owen Hughes
14 Sep 21
Financial summary
| Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 254.30 mm | 254.30 mm | 254.30 mm | 254.30 mm | 254.30 mm | 254.30 mm |
| Cash burn (monthly) | (no burn) | 1.57 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 32.70 mm | n/a | n/a | n/a | n/a |
| Cash remaining | n/a | 221.59 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | n/a | 141.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2022
10.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 179.68 mm |
| Total shares | 7.61 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Atlas Venture Fund VIII | 3.92 mm | $72.28 mm |
| SNY Sanofi | 3.68 mm | $107.40 mm |